Inhibition of THC-induced effects on the central nervous system and heart rate by a novel CB1 receptor antagonist AVE1625.
L Zuurman, C Roy, R C Schoemaker, A Amatsaleh, L Guimaeres, J L Pinquier, A F Cohen, J M A van Gerven
Journal of psychopharmacology (Oxford, England) March 2010 DOI: 10.1177/0269881108096509 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Randomized controlled trial Peer reviewed |
|---|---|
| Interventions | AVE1625 THC |
| Dose | AVE1625 20 mg (lowest dose) |
| Measures | Visual Analogue Scales 'alertness', 'feeling high', 'external perception', 'body sway', 'heart rate', electroencephalography |
| Topics | Cannabis |
| Key findings | AVE1625 antagonized THC-induced effects on alertness, feeling high, external perception, body sway, and heart rate, with inhibition observed at the lowest dose of 20 mg. AVE1625 alone had no effect on psychological or behavioral parameters or heart rate. The authors conclude that AVE1625 penetrates the brain and antagonizes THC effects at doses at or above 20 mg. |
Abstract
CB1 antagonists such as AVE1625 are potentially useful in the treatment of obesity, smoking cessation and cognitive impairment. Proof of pharmacological action of AVE1625 in the brain can be given by antagonising the effects of delta-9-tetrahydrocannabinol (THC), a CB1/CB2 agonist. Inhibition of THC-induced effects by AVE1625 was observed on Visual Analogue Scales 'alertness', 'feeling high', 'external perception', 'body sway' and 'heart rate'. Even the lowest dose of AVE1625 20 mg inhibited most of THC-induced effects. AVE1625 did not have any effect on psychological and behavioural parameters or heart rate by itself. After THC and AVE1625 administration, changes on electroencephalography were observed. This study shows a useful method for studying the effects of CB1 antagonists. AVE1625 penetrates the brain and antagonises THC-induced effects with doses at or above 20 mg.